HCV - Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005

Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005
FinanzNachrichten - Feb 09 6:57 AM
ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, ( Nachrichten / Aktienkurs ) Inc. announced financial results for the quarter and full-year periods ended December 31, 2005, and reiterated guidance for financial results anticipated for 2006.Save to My Web

Migenix: infectious ambitions in hepatitis
Pharmaceutical Business Review - Jan 25 5:56 PM
Migenix has confirmed plans to initiate a viral kinetics study with celgosivir in hepatitis C.Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 12:56 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web

YOU ARE HERE:
Aidsmap - Jan 23 5:06 PM
Fatigue is more than twice as prevalent as depression during anti-hepatitis C (HCV) treatment in HIV-positive individuals, according to a study presented to the Second International Workshop on HIV and Hepatitis Coinfection, held in Amsterdam earlier this month.Save to My Web